Gut Microbiota Composition Correlates with Disease Severity in Myelodysplastic Syndrome
Abstract
The myelodysplastic syndrome (MDS) is a heterogeneous group of clonal disorders of hematopoietic progenitor cells related to ineffective hematopoiesis and an increased risk of transformation to acute myelogenous leukemia. MDS is divided into categories, namely lineage dysplasia (MDS-SLD), MDS with ring sideroblasts (MDS-RS), MDS with multilineage dysplasia (MDS-MLD), MDS with excess blasts (MDS-EB). The International Prognostic Classification System (IPSS) ranks the patients as very low, low, intermediate, high, and very high based on disease evolution and survival rates. Evidence points to toll-like receptor (TLR) abnormal signaling as an underlying mechanism of this disease, providing a link between MDS and immune dysfunction. Microbial signals, such as lipopolysaccharides from gram-negative bacteria, can activate or suppress TLRs. Therefore, we hypothesized that MDS patients present gut microbiota alterations associated with disease subtypes and prognosis. To test this hypothesis, we sequenced the 16S rRNA gene from fecal samples of 30 MDS patients and 16 healthy elderly controls. We observed a negative correlation between Prevotella spp. and Akkermansia spp. in MDS patients compared with the control group. High-risk patients presented a significant increase in the genus Prevotella spp. compared to the other risk categories. There was a significant reduction in the abundance of the genus Akkermansia spp. in high-risk patients compared with low- and intermediate-risk. There was a significant decrease in the genus Ruminococcus spp. in MDS-EB patients compared with controls. Our findings show a new association between gut dysbiosis and higher-risk MDS, with a predominance of gram-negative bacteria.
2. Ria R, Moschetta M, Reale A, et al. Managing myelodysplastic symptoms in elderly patients. Clin Interv Aging. 2009:4:413-23.
3. Bejar R, Abdel-Wahab O. The importance of subclonal genetic events in MDS. Blood. 2013;122 (22): 3550–3551.
4. Greenberg P, Tuechler H. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120 (12): 2454–2465.
5. Lindsley RC, Ebert BL. Molecular pathophysiology of myelodysplastic syndromes. Annu Rev Pathol. 2013:8:21-47.
6. Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26(10): 1549–1556.
7. Yang L, Qian Y, Eksioglu E, et al. The inflammatory microenvironment in MDS. Cell Mol Life Sci. 2015; 72(10):1959-66.
8. Peyssonnaux C, Zinkernagel AS, Datta V, et al. TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood. 2006;107(9): 3727–3732.
9. Cines DB, Liebman H, Stasi R. Pathobiology of Secondary Immune Thrombocytopenia. Semin Hematol. 2009 ;46(1 Suppl 2):S2-14.
10. Taur Y, Jenq RR, Perales MA, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood. 2014; 124(7): 1174–1182.
11. Brandsma E, Kloosterhuis NJ, Koster M, et al. A Proinflammatory Gut Microbiota Increases Systemic Inflammation and Accelerates Atherosclerosis. Circ Res. 2019; 124(1):94-100.
12. Anderson M, Gorley RN, Clarke KR. PERMANOVA + for PRIMER user manual. 2008. 1: 1:218.
13. Blander JM, Longman RS, Iliev ID, et al. Regulation of inflammation by microbiota interactions with the host. Nat Immunol. 2017;18(8):851-860.
14. Yan H, Baldridge MT, King KY. Hematopoiesis and the bacterial microbiome. Blood. 2018;132(6): 559–564.
15. Huijuan J, Xiaoyu Z, Mengtong Z, et al. Gut Microbiome and Plasma Metabolomic Analysis in Patients with Myelodysplastic Syndrome. Oxid Med Cell Longev. 2022:2022:1482811.
16. Maggioni G, Bersanelli M, Travaglino E, et al. A sex-informed approach to improve the personalized decision making process in myelodysplastic syndromes: a multicentre, observational cohort study. Lancet Haematol; 2023; 10(2): e117–28.
17. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011; 473 (7346):174-80.
18. Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. ELife. 2013; 2: e01202.
19. Su T, Liu R, Lee A, et al. Altered intestinal microbiota with increased abundance of prevotella is associated with high risk of diarrhea-predominant irritable bowel syndrome. Gastroenterol Res Pract. 2018; 2018:6961783.
20. Leimkühler NB, Schneider RK. Inflammatory bone marrow microenvironment. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):294-302.
21. Iljazovic A, Roy U, Gálvez EJC, et al. Perturbation of the gut microbiome by Prevotella spp. enhances host susceptibility to mucosal inflammation. Mucosal Immunol. 2021;14(1):113-124.
22. Maayan Levy, Thaiss CA, Zeevi D, et al. Microbiota-Modulated Metabolites Shape the Intestinal Microenvironment by Regulating NLRP6 Inflammasome Signaling. Cell. 2015; 163(6):1428-43.
23. Cluzeau T, McGraw KL, Irvine B, et al. Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes. Haematologica. 2017; 102(12): 2015–2020.
24. Flint HJ, Duncan SH, Louis P. The impact of nutrition on intestinal bacterial communities. Curr Opin Microbiol. 2017:38:59-65.
25. Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut microbes. 2016; 7(3): 189–200.
26. Crost EH, Le Gall G, Laverde-Gomez JA, et al. Mechanistic insights into the cross-feeding of Ruminococcus gnavus and Ruminococcus bromii on host and dietary carbohydrates. Front Microbiol. 2018:9:2558.
27. Severyn CJ, Brewster R, Andermann TM. Microbiota modification in hematology: Still at the bench or ready for the bedside? Hematology Am Soc Hematol Educ Program. 2019;2019(1):303-314.
28. Zeevi D, Korem T, Zmora N, et al. Personalized Nutrition by Prediction of Glycemic Responses. Cell. 2015;163(5): 1079–1094.
29. Zaki H, Boyd KL, Kastan MB, et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity. 2010; 32(3): 379–391.
30. Meers S, Kasran A, Boon L, et al. Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40–CD40L interactions with T helper cells. Leukemia. 2007. 21(12): 2411–2419.
31. Qin H, Wilson CA, Lee SJ, et al. LPS induces CD40 gene expression through the activation of NF-kappaB and STAT-1alpha in macrophages and microglia. Blood. 2005; 106(9): 3114–3122.
32. Barreyro L, Chlon TM, Starczynowski DT. Chronic immune response dysregulation in MDS pathogenesis. Blood. 2018; 132(15): 1553–1560.
33. de Sousa JC, da Nóbrega Ito M, Costa MB, et al. Dysregulation of interferon regulatory genes reinforces the concept of chronic immune response in myelodysplastic syndrome pathogenesis. Hematol Oncol.2019;37(4):523-526.
34. Yang Y, Wang H, Kouadir M, et al. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019;10(2):128.
35. Woerner J, Huang Y, Hutter S, et al. Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes. Nat Commun; 2022;13(1):1038.
36. Derrien M, Belzer C, de Vos WM. Akkermansia muciniphila and its role in regulating host functions. Microb Pathog. 2017;106:171-181.
37. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91-97.
Files | ||
Issue | Vol 18 No 2 (2024) | |
Section | Original Article(s) | |
DOI | https://doi.org/10.18502/ijhoscr.v18i2.15377 | |
Keywords | ||
Gut microbiota composition Myelodysplastic Syndromes 16S rRNA gene MD Elderly people |
Rights and permissions | |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |